摘要
本文报道乐瓦停(Lovastatin)对伴有高脂血症的陈旧性心肌梗塞(OMI)、非胰岛素依赖型糖尿病(NIDDM)及肾病综合征(NS)三组患者34例的降血脂疗效。结果显示,与治疗前比,服安慰剂4周,各组血脂均无明显变化;服乐瓦停4周,各组血脂均有明显改善,继续服药,疗效稳定。服乐瓦停12周,TC降34.1%(P<0.001),LDL-C降43.6%(P<0.001),TC/HDL-C降35.6%(P<0.001),TG降30.8%(P<0.01),OMI组及NIDDM组ApoB都明显下降(P<0.01—0.001),Apo A Ⅰ/Apo B比值都明显上升(P<0.01—0.001);三组Apo A-Ⅰ、HDL-C及NS组的Apo B及Apo A-Ⅰ/Apo B比值均未见明显变化(P>0.05)。疗程中,乐瓦停与环磷酰胺或雷公藤合用的2例SGPT均明显升高,停药后迅速回降。本文未见其它重要副作用。
This study presented a clinical evaluation of lovastatin in the treatment of primary hyperlipidemia associated with old myocardial infarction (OMI, 12 cases), and secondary hyperlipidemia associated with non-insulin-dependent diabetes mellitus (NIDDM, 11 cases), and nephrotic syndrome (NS, 11 cases). After treatment with lovastatin for 12 weeks (40mg QD), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride(TG) and total cholesterol/high density lipoprotein cholesterol (TC/HDL-C) reduced by 34.1% (p<0.001), 43.6% (p<0.001), 30.8% (p<0.01) and 35.6% (p<0.001) respcetively in comparing with baseline values. In OMI group and NIDDM group, apolipoprotein B reduced by 41.0% (p<0.001) and 25.6% (p<0.01) respectively, apolipoprotein A-I/apolipoprotein B (Apo AI/ Apo B) elevated by 53.4% (p<0.001) and 34.8% (p<0.01) respectively. There were no significant changes of Apo A-I and HDL-C in all groups and there was no significant change of Apo A-I/Apo B in NS group.
During therapy, SCPT level increased to more than three times the upper limit of normal in two patients who had taken lovastatin and triptrerygium wilfordii or lovastatin and cyclophosphamide concurrently. After withdrawing of those drugs, SCPT level returned to normal. No significant side-effect was found in the course of treatment with lovastatin alone.
出处
《中国循环杂志》
CSCD
1992年第1期30-32,共3页
Chinese Circulation Journal
关键词
高血脂病
胆固醇
乐瓦停
Hyperlipidemia
Cholesterol
Lovastatin
